X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Frontiers in Oncology

期刊標題檢索 FRONT ONCOL 最新評論: OP, how did you solve this problem? Please provide evidence of colla... (2024-06-17)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Frontiers in Oncology]您好,您是該頁面的第 413340 位訪客。

期刊簡介
期刊名稱Frontiers in Oncology Frontiers in Oncology
LetPub Score
7.3
56 ratings
Rate

Reputation
7.4

Influence
6.5

Speed
8.4

期刊簡稱FRONT ONCOL
ISSN2234-943X
h-index60
CiteScore
CiteScoreSJRSNIPCiteScore Rank
6.201.0660.831
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q2120 / 404
Category: Medicine
Subcategory: Cancer Research
Q2100 / 230

自引率 (2023-2024)5.70%自引率趨勢
掲載範囲
Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
官方網站https://www.frontiersin.org/journals/oncology
在線稿件提交https://www.frontiersin.org/journals/oncology#author-guidelines
開放訪問Yes
出版商Frontiers Media S.A.
主題領域Biochemistry, Genetics and Molecular Biology
出版國/地區Switzerland
發行頻率
創刊年0
每年文章數4475每年文章數趨勢
黃金OA百分比99.56%
OA Related Info
APC: Yes( USD3295; )
APC waiver:Check Notes
Other charges: No
Keywords: cancer research、clinical oncology、cancer genetics、molecular targets、surgical oncology
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ2107/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2234-943X%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 14 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Frontiers in Oncology】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Cancer CommunicationsH-index: 0

    CiteScore: 25.50
    CELLULAR ONCOLOGYH-index: 0

    CiteScore: 10.30
    Translational OncologyH-index: 41

    CiteScore: 8.40
    Journal of Gastric CancerH-index: 22

    CiteScore: 4.30
    Molecular and Cellular OncologyH-index: 0

    CiteScore: 3.20
    Clinical and Experimental MorphologyH-index: 0

    CiteScore: 0.60
    Critical Reviews in OncogenesisH-index: 0

    CiteScore: 1.70
    International Journal of Medical BiochemistryH-index: 0

    CiteScore: 0.50
    Advances in Cancer Biology MetastasisH-index: 0

    CiteScore: 2.40
    學科內最受檢索的期刊 頁面查看次數
    Translational Oncology65649
    Cancer Communications55293
    CELLULAR ONCOLOGY31423
    Journal of Gastric Cancer16405
    Molecular and Cellular Oncology4886
    Critical Reviews in Oncogenesis3516
    Clinical and Experimental Morphology2517
    Advances in Cancer Biology Metastasis692
    International Journal of Medical Biochemistry554
  •  

    Frontiers in Oncology Frontiers in Oncology
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/139)
  [Frontiers in Oncology] 的評論撰寫評論
作者: 阿锐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-17 08:59:58 評論於
OP, how did you solve this problem?

Please provide evidence of collaboration between different members of the author group. This could take the form of:
1. Email messages between authors before the initial submission
2. Chat messages between authors before the initial submission that have been translated into English
3. Annotated manuscript drafts with comments predating the initial submission
If you are a sole author, please provide all draft versions of your article. The initial review stage requires this author involvement in the evidence, how did you all handle it?
(0) 讚! | 阿锐

作者: 阿锐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-17 08:59:08 評論於
Has your issue been resolved?
(0) 讚! | 阿锐

作者: 猪蹄分你一半


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-08 15:41:29 評論於
It just started this month, I'm going to withdraw my submission, I have no other choice
(0) 讚! | 猪蹄分你一半

作者: 刘小白白白


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-07 09:32:59 評論於
Do you know the reason why? I also received the same reply
(0) 讚! | 刘小白白白

作者: 猪蹄分你一半


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-01 11:59:29 評論於
Please provide evidence of collaboration involving different members of the author group. This can take the following forms:
1. Email messages between authors before the initial submission.
2. Chat messages between authors before the initial submission, translated into English.
3. Annotated manuscript drafts, where comments predate the initial submission.
If you are a single author, please provide all draft versions of your article. The initial review stage requires authors to submit this evidence of their participation. How do you guys handle this?
(0) 讚! | 猪蹄分你一半

作者: wludo


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-28 20:12:02 評論於
Why hasn't the editor been assigned after almost three weeks since submission? I'm getting really anxious
(0) 讚! | wludo

作者: 代卉来了


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-28 08:33:57 評論於
I used my academic email to submit it, and I have received the review back. You should try using your academic email
(0) 讚! | 代卉来了

作者: 孤云大渊献


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-26 20:16:55 評論於
May I ask how long it takes to assign an editor? I have been waiting for almost a month and have not been assigned an editor yet
(0) 讚! | 孤云大渊献

作者: 医研丁真


領域: 医学
審稿時間: 1.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-26 19:08:37 評論於
I feel like this journal shouldn't be this slow, right?
(1) 讚! | 医研丁真

作者: 白云鸿彩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-21 13:39:31 評論於
I have also sent two reminder emails, but still haven't received a reply. I don't know what's going on
(0) 讚! | 白云鸿彩

作者: 云居金宇


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-18 18:19:16 評論於
Hello, have you accepted it finally? I'm wondering if I should withdraw my submission
(0) 讚! | 云居金宇

作者: 骨架白玉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-17 20:52:21 評論於
Have you accepted the article?
(0) 讚! | 骨架白玉

作者: 静心冷玉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-17 20:00:48 評論於
Please translate the following passage into English and Japanese, and title them with ":" and ":"
(0) 讚! | 静心冷玉

作者: 泄矢海淇


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-02 23:06:30 評論於
This submission has been with the editors for almost a month, what should I do?
(0) 讚! | 泄矢海淇

作者: 华清从凝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-01 16:06:01 評論於
Review Speed: 3.0 | Submission Hit Rate: 50.0 Emphasized Research Direction: Tumor Cell Immunity Experience Sharing: Share the submission experience, which lasted 6 months. The Initial Validation phase was too long, and because there were already articles that could meet graduation requirements, I did not urge the editor. I hope that everyone who sees this (especially little friends who need articles for graduation) can get accepted
(0) 讚! | 华清从凝

作者: 五虎涵亮


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-20 19:11:25 評論於
Am I the same, why is this? Did I violate any rules of his magazine?
(0) 讚! | 五虎涵亮

作者: 奥尔德里奇比尔博姆


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-15 08:36:51 評論於
And you, how did you solve the problem in the end?
(0) 讚! | 奥尔德里奇比尔博姆

作者: 仰天侠


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-29 09:28:37 評論於
It has been six or seven months since I submitted my work, and I still haven't found an editor. I have reminded them several times, and the editor recommendations have been sent twice, but I keep receiving apologies for the delay without any progress. What's going on with the magazine's editorial department? Why is everyone so slow?
(3) 讚! | 仰天侠

作者: 邻家泽恩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-25 19:13:34 評論於
How long does it usually take at the initial stage? It's been two weeks and I haven't made any progress yet
(1) 讚! | 邻家泽恩

作者: 邻家泽恩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-25 12:45:28 評論於
Brother, have you uploaded it finally?
(0) 讚! | 邻家泽恩

作者: 邻家泽恩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-25 12:06:20 評論於
How long does it take in the initial stage? I haven't started for two weeks
(0) 讚! | 邻家泽恩

作者: 明冠文柏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-23 15:52:18 評論於
How should we respond to the comments from the reviewers, teacher?
(0) 讚! | 明冠文柏

作者: 黄土代阳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-22 20:34:06 評論於
Emphasis on research direction: Tumor experience sharing: All the experts, may I ask what does this rejection mean?
(0) 讚! | 黄土代阳

作者: 邻家泽恩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-20 13:34:29 評論於
Heavy research focus: Tumors; Immunotherapy; Bioinformatics experience sharing: How long does it take to assign an editor? It's been 4.5 days in initial validation... Bioinformatics has conducted 6 verification experiments again, not sure if it's stable or not
(0) 讚! | 邻家泽恩

作者: Heymanr


領域: 计算机科学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-20 09:39:27 評論於
The system shows that both reviewers have approved, why haven't we received any news in almost a month?
(0) 讚! | Heymanr

首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/139)

開始撰寫 [Frontiers in Oncology] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*